Update shared on30 Jul 2025
Fair value Decreased 30%The sharp reduction in Puma Biotechnology’s price target is primarily driven by a marked shift from modest expected revenue growth to anticipated revenue contraction, with valuation multiples increasing accordingly, resulting in a new consensus target of $3.00 (down from $4.29).
What's in the News
- Dropped from multiple Russell growth and small-cap indices, including Russell 2000, 2500, 3000, Microcap, and Small Cap Comp Growth benchmarks.
- Board approved amended and restated bylaws to align with recent Delaware law updates and incorporated related minor changes.
- Issued earnings guidance for Q2 2025 (net product revenue: $48–$50 million; net loss: $4–$6 million) and full year 2025 (net product revenue: $192–$198 million; net income: $23–$28 million).
Valuation Changes
Summary of Valuation Changes for Puma Biotechnology
- The Consensus Analyst Price Target has significantly fallen from $4.29 to $3.00.
- The Consensus Revenue Growth forecasts for Puma Biotechnology has significantly fallen from 0.3% per annum to -2.5% per annum.
- The Future P/E for Puma Biotechnology has significantly risen from 13.01x to 22.11x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.